DE60035575D1 - Verwendubg von 3-hydroxy-3-methylglutaryl coenzym a reduktase inhibitoren zur herstellung eines medikaments zur behandlung der diabetischen neuropathie - Google Patents
Verwendubg von 3-hydroxy-3-methylglutaryl coenzym a reduktase inhibitoren zur herstellung eines medikaments zur behandlung der diabetischen neuropathieInfo
- Publication number
- DE60035575D1 DE60035575D1 DE60035575T DE60035575T DE60035575D1 DE 60035575 D1 DE60035575 D1 DE 60035575D1 DE 60035575 T DE60035575 T DE 60035575T DE 60035575 T DE60035575 T DE 60035575T DE 60035575 D1 DE60035575 D1 DE 60035575D1
- Authority
- DE
- Germany
- Prior art keywords
- coenzym
- methylglutaryl
- medicament
- hydroxy
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9902591.8A GB9902591D0 (en) | 1999-02-06 | 1999-02-06 | Pharmaceutical compositions |
GB9902594 | 1999-02-06 | ||
GB9902591 | 1999-02-06 | ||
GBGB9902594.2A GB9902594D0 (en) | 1999-02-06 | 1999-02-06 | Pharmaceutical compositions |
PCT/GB2000/000280 WO2000045818A1 (en) | 1999-02-06 | 2000-02-01 | Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60035575D1 true DE60035575D1 (de) | 2007-08-30 |
DE60035575T2 DE60035575T2 (de) | 2008-04-03 |
Family
ID=26315085
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60045168T Expired - Lifetime DE60045168D1 (de) | 1999-02-06 | 2000-02-01 | Kombinationspräparate enthaltend (E)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r,5s)-3,5-dihydroxyhept-6-enoic Säure |
DE60035575T Expired - Lifetime DE60035575T2 (de) | 1999-02-06 | 2000-02-01 | Verwendubg von 3-hydroxy-3-methylglutaryl coenzym a reduktase inhibitoren zur herstellung eines medikaments zur behandlung der diabetischen neuropathie |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60045168T Expired - Lifetime DE60045168D1 (de) | 1999-02-06 | 2000-02-01 | Kombinationspräparate enthaltend (E)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r,5s)-3,5-dihydroxyhept-6-enoic Säure |
Country Status (34)
Country | Link |
---|---|
US (4) | US6894058B1 (de) |
EP (2) | EP1150678B1 (de) |
JP (3) | JP2002536332A (de) |
KR (1) | KR100699757B1 (de) |
CN (1) | CN1196488C (de) |
AR (1) | AR025512A1 (de) |
AT (2) | ATE367162T1 (de) |
AU (1) | AU763970B2 (de) |
BR (1) | BR0007996A (de) |
CA (1) | CA2368186C (de) |
CY (2) | CY1106879T1 (de) |
CZ (2) | CZ302893B6 (de) |
DE (2) | DE60045168D1 (de) |
DK (2) | DK1897546T3 (de) |
EE (2) | EE05621B1 (de) |
ES (2) | ES2286995T3 (de) |
GB (1) | GB0001662D0 (de) |
HK (2) | HK1041223A1 (de) |
HU (1) | HU227642B1 (de) |
IL (3) | IL144730A0 (de) |
IS (2) | IS2793B (de) |
MX (1) | MXPA01007821A (de) |
MY (1) | MY138289A (de) |
NO (1) | NO330400B1 (de) |
NZ (3) | NZ525419A (de) |
PL (1) | PL198098B1 (de) |
PT (2) | PT1150678E (de) |
RU (1) | RU2239456C2 (de) |
SI (2) | SI1150678T1 (de) |
SK (2) | SK286854B6 (de) |
TR (1) | TR200102229T2 (de) |
TW (1) | TWI230067B (de) |
WO (1) | WO2000045818A1 (de) |
ZA (1) | ZA200105885B (de) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0001662D0 (en) * | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
US6555540B1 (en) * | 1999-06-30 | 2003-04-29 | Pfizer Inc | Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors |
GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
CA2399463A1 (en) * | 2000-02-10 | 2001-08-16 | Takeda Chemical Industries, Ltd. | Combination drug |
GB0003305D0 (en) * | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
DE10025308A1 (de) * | 2000-05-23 | 2001-11-29 | Bayer Ag | Kombination von Cerivastatin mit ACE Inhibitoren und ihre Verwendung in Arzneimitteln |
AR033390A1 (es) * | 2000-08-22 | 2003-12-17 | Novartis Ag | Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes |
PE20020323A1 (es) * | 2000-08-22 | 2002-06-13 | Novartis Ag | COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE) |
US20060089389A1 (en) | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
IL155173A0 (en) * | 2000-10-12 | 2003-10-31 | Nissan Chemical Ind Ltd | Prophylactic and therapeutic agent for diabetic complications |
HUP0303497A3 (en) * | 2000-10-18 | 2006-02-28 | Pfizer Prod Inc | Pharmaceutical compositions containing combination of statins and sorbitol dehydrogenase inhibitors |
AU2002215160A1 (en) * | 2000-11-30 | 2002-06-11 | Pfizer Products Inc. | Combination of gaba agonists and aldose reductase inhibitors |
US20030171407A1 (en) * | 2002-03-07 | 2003-09-11 | Upsher-Smith Laboratories, Inc. | Composition for reducing blood glucose and cholesterol |
WO2003077912A1 (en) * | 2002-03-20 | 2003-09-25 | The University Of Queensland | Method of treatment and/or prophylaxis |
AR039090A1 (es) * | 2002-03-22 | 2005-02-09 | Novartis Ag | Combinacion de compuestos organicos |
JP4395633B2 (ja) * | 2002-08-29 | 2010-01-13 | 学校法人鈴鹿医療科学大学 | 非神経細胞の神経細胞への分化成熟法、該組成物と該組成物探索法 |
US7179941B2 (en) | 2003-01-23 | 2007-02-20 | Sanofi-Aventis Deutschland Gmbh | Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use |
DE10302452B4 (de) * | 2003-01-23 | 2005-02-24 | Aventis Pharma Deutschland Gmbh | Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung |
EP1618893A4 (de) * | 2003-04-28 | 2009-08-12 | Sankyo Co | Mittel zur verstärkung der zuckeraufnahmefähigkeit |
JP2005232151A (ja) * | 2003-04-28 | 2005-09-02 | Iichiro Shimomura | 糖取り込み能増強剤 |
US9345671B2 (en) | 2003-04-28 | 2016-05-24 | Daiichi Sankyo Company, Limited | Adiponectin production enhancer |
US20090082407A1 (en) * | 2004-06-18 | 2009-03-26 | Biostratum, Inc. | Pyridoxamine for the Treatment of Diabetic Kidney Disease |
CA2529538C (en) * | 2003-06-20 | 2011-04-26 | Biostratum, Inc. | Pyridoxamine for the treatment of diabetic kidney disease |
EP1510208A1 (de) * | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Metformin-Statin-Kombination enthaltende pharmazeutische Zusammensetzungen |
US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
AU2003269484A1 (en) * | 2003-09-11 | 2005-03-29 | Biocon Limited | Salt of atorvastatin with metformin |
GB0322552D0 (en) * | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
WO2005033067A1 (en) * | 2003-10-07 | 2005-04-14 | Biocon Limited | SALT OF 1,2,6,7,8,8A-HEXAHYDRO-β,δ,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-, (βR,δ R,1S,2S,6S,8S,8AR)- 1-NAPHTHALENEHEPTANOIC ACID WITH N,N-DIMETHYL-IMIDODICARBONIMIDIC DIAMIDE |
KR100715114B1 (ko) * | 2005-02-19 | 2007-05-10 | 한국유나이티드제약 주식회사 | 당뇨병 치료를 위한 약학적 조성물 |
CN101632673B (zh) * | 2008-07-24 | 2011-08-10 | 鲁南制药集团股份有限公司 | 含有氯沙坦、吡格列酮和瑞舒伐他汀的药物组合物及其新用途 |
DK2326632T3 (en) * | 2008-09-06 | 2017-09-18 | Bionevia Pharmaceuticals Inc | New choline crystal of epalrestate |
EP2196476A1 (de) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antikörperformulierung |
IN2014CN04119A (de) | 2011-11-15 | 2015-07-10 | Reddys Lab Ltd Dr | |
WO2015053589A1 (ko) * | 2013-10-11 | 2015-04-16 | 가톨릭대학교 산학협력단 | 메트포민 및 스타틴의 복합제를 이용한 자가면역질환의 예방 또는 치료용 조성물 |
KR101579656B1 (ko) * | 2013-12-12 | 2015-12-22 | 가천대학교 산학협력단 | 프라바스타틴과 발사르탄을 포함하는 약학 조성물 |
CN110747206B (zh) * | 2019-11-05 | 2021-11-23 | 昆明理工大学 | 3-羟基-3-甲基戊二酸单酰辅酶a还原酶基因rkhmgr及其应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
CA2040865C (en) | 1990-05-15 | 2002-07-23 | James L. Bergey | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor |
US5298497A (en) | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
US5140012A (en) | 1990-05-31 | 1992-08-18 | E. R. Squibb & Sons, Inc. | Method for preventing onset of restenosis after angioplasty employing pravastatin |
US5622985A (en) | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
US5190970A (en) | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
CA2052014A1 (en) * | 1990-10-19 | 1992-04-20 | Henry Y. Pan | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
US5130333A (en) * | 1990-10-19 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Method for treating type II diabetes employing a cholesterol lowering drug |
JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
GB9208116D0 (en) * | 1992-04-13 | 1992-05-27 | Ici Plc | Therapeutic agents |
DE69325574T2 (de) | 1992-04-13 | 2000-03-16 | Zeneca Ltd | ANGIOTENSIN-II-ANTAGONISTEN GEGEN ERKRANKUNGEN; DIE MIT EINER EINGESCHRäNKTEN; NEURONALEN LEITUNGSGESCHWINDIGKEIT VERBUNDEN SIND, INSBESONDERE DIABETISCHE NEUROPATHIE |
AU1095695A (en) | 1993-11-09 | 1995-05-29 | Brigham And Women's Hospital | Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction |
WO1995026188A1 (en) | 1994-03-29 | 1995-10-05 | Merck & Co., Inc. | Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles |
TW438587B (en) | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
CA2577233C (en) | 1996-04-05 | 2009-08-18 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition containing angiotensin ii antagonist |
GB9714274D0 (en) * | 1997-07-08 | 1997-09-10 | Zeneca Ltd | Pharmaceutical composition |
GT199800126A (es) | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
GB0001662D0 (en) * | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
US6262076B1 (en) * | 2000-01-28 | 2001-07-17 | Ajinomoto Co., Inc. | Pharmaceutical composition for use in the treatment of diabetic neuropathy |
GB0322552D0 (en) * | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
-
2000
- 2000-01-26 GB GBGB0001662.6A patent/GB0001662D0/en not_active Ceased
- 2000-01-31 AR ARP000100409A patent/AR025512A1/es unknown
- 2000-02-01 EP EP00901744A patent/EP1150678B1/de not_active Expired - Lifetime
- 2000-02-01 RU RU2001124665/15A patent/RU2239456C2/ru active
- 2000-02-01 CZ CZ20110341A patent/CZ302893B6/cs not_active IP Right Cessation
- 2000-02-01 JP JP2000596938A patent/JP2002536332A/ja active Pending
- 2000-02-01 EE EEP201200015A patent/EE05621B1/xx unknown
- 2000-02-01 MX MXPA01007821A patent/MXPA01007821A/es not_active IP Right Cessation
- 2000-02-01 AU AU23047/00A patent/AU763970B2/en not_active Ceased
- 2000-02-01 KR KR1020017009907A patent/KR100699757B1/ko not_active IP Right Cessation
- 2000-02-01 WO PCT/GB2000/000280 patent/WO2000045818A1/en active Application Filing
- 2000-02-01 CA CA002368186A patent/CA2368186C/en not_active Expired - Fee Related
- 2000-02-01 SK SK1110-2001A patent/SK286854B6/sk not_active IP Right Cessation
- 2000-02-01 ES ES00901744T patent/ES2286995T3/es not_active Expired - Lifetime
- 2000-02-01 CZ CZ20012806A patent/CZ302881B6/cs not_active IP Right Cessation
- 2000-02-01 SK SK5109-2008A patent/SK287792B6/sk not_active IP Right Cessation
- 2000-02-01 TR TR2001/02229T patent/TR200102229T2/xx unknown
- 2000-02-01 SI SI200030962T patent/SI1150678T1/sl unknown
- 2000-02-01 NZ NZ52541900A patent/NZ525419A/xx not_active IP Right Cessation
- 2000-02-01 DE DE60045168T patent/DE60045168D1/de not_active Expired - Lifetime
- 2000-02-01 ES ES07008956T patent/ES2352803T3/es not_active Expired - Lifetime
- 2000-02-01 NZ NZ536433A patent/NZ536433A/en not_active IP Right Cessation
- 2000-02-01 DK DK07008956.0T patent/DK1897546T3/da active
- 2000-02-01 HU HU0105138A patent/HU227642B1/hu not_active IP Right Cessation
- 2000-02-01 NZ NZ513061A patent/NZ513061A/xx not_active IP Right Cessation
- 2000-02-01 AT AT00901744T patent/ATE367162T1/de active
- 2000-02-01 PT PT00901744T patent/PT1150678E/pt unknown
- 2000-02-01 US US09/889,409 patent/US6894058B1/en not_active Expired - Lifetime
- 2000-02-01 CN CNB008034974A patent/CN1196488C/zh not_active Expired - Lifetime
- 2000-02-01 EP EP07008956A patent/EP1897546B1/de not_active Expired - Lifetime
- 2000-02-01 PL PL350312A patent/PL198098B1/pl unknown
- 2000-02-01 AT AT07008956T patent/ATE485823T1/de active
- 2000-02-01 DE DE60035575T patent/DE60035575T2/de not_active Expired - Lifetime
- 2000-02-01 BR BR0007996-0A patent/BR0007996A/pt not_active Application Discontinuation
- 2000-02-01 SI SI200031063T patent/SI1897546T1/sl unknown
- 2000-02-01 EE EEP200100405A patent/EE05556B1/xx not_active IP Right Cessation
- 2000-02-01 IL IL14473000A patent/IL144730A0/xx unknown
- 2000-02-01 PT PT07008956T patent/PT1897546E/pt unknown
- 2000-02-01 DK DK00901744T patent/DK1150678T3/da active
- 2000-02-03 TW TW089101895A patent/TWI230067B/zh not_active IP Right Cessation
- 2000-02-04 MY MYPI20000412A patent/MY138289A/en unknown
-
2001
- 2001-07-17 ZA ZA200105885A patent/ZA200105885B/en unknown
- 2001-07-20 IS IS6016A patent/IS2793B/is unknown
- 2001-08-03 NO NO20013812A patent/NO330400B1/no not_active IP Right Cessation
- 2001-08-05 IL IL144730A patent/IL144730A/en not_active IP Right Cessation
-
2002
- 2002-04-22 HK HK02103012A patent/HK1041223A1/xx unknown
-
2004
- 2004-09-08 US US10/935,747 patent/US20050209128A1/en not_active Abandoned
-
2007
- 2007-09-19 CY CY20071101207T patent/CY1106879T1/el unknown
-
2008
- 2008-08-11 US US12/222,534 patent/US20090186908A1/en not_active Abandoned
- 2008-08-21 HK HK08109378.5A patent/HK1118209A1/xx unknown
-
2010
- 2010-09-21 IL IL208330A patent/IL208330A0/en unknown
- 2010-12-16 CY CY20101101157T patent/CY1110992T1/el unknown
-
2011
- 2011-03-15 US US13/048,377 patent/US20120041010A1/en not_active Abandoned
- 2011-08-23 IS IS8978A patent/IS2820B/is unknown
- 2011-09-29 JP JP2011213694A patent/JP2012051898A/ja active Pending
-
2013
- 2013-11-20 JP JP2013239770A patent/JP2014065718A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60035575D1 (de) | Verwendubg von 3-hydroxy-3-methylglutaryl coenzym a reduktase inhibitoren zur herstellung eines medikaments zur behandlung der diabetischen neuropathie | |
ATE204754T1 (de) | Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie | |
ATE417606T1 (de) | Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege | |
ATE248599T1 (de) | Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen | |
DE60022916D1 (de) | Reboxetin zur Behandlung von peripheren Neuropathien | |
DE50206657D1 (de) | Pharmazeutische zusammensetzung zur behandlung von multiple sklerose | |
ATE342728T1 (de) | Zubereitung zur behandlung von einer neurologischen erkrankung | |
DE60320007D1 (de) | Phenethanolamin-derivate zur behandlung von atemwegserkrankungen | |
ATE344253T1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
DE60124684D1 (de) | Sulfonamido-substituierte verbrückte bicycloalkylderivative | |
DE60329316D1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
DE60239648D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Asthma | |
ATE487493T1 (de) | Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungen | |
DE60100625D1 (de) | Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina | |
DE69910202D1 (de) | EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden | |
DE50013843D1 (de) | Arzneimittel zur behandlung von darmerkrankungen | |
DE60318327D1 (de) | Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe | |
DE59914712D1 (de) | Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden | |
DE50012014D1 (de) | Verwendung einer pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit | |
ATE289196T1 (de) | Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen | |
DE60128911D1 (de) | Verwendung von l-threo-methylphenidat zur herstellung eines medikamentes zur behandlung von psychischen erkrankungen | |
DE60001599D1 (de) | Verfahren zur Herstellung von cis-1-2-[4-(6-Methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl-pyrrolidin | |
ATE285764T1 (de) | Rivastigmine zur behandlung von augenerkrankungen | |
DE50004234D1 (de) | Brandsohle und Verwendung derselben zur Herstellung eines Schuhs | |
DE50012667D1 (de) | Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |